论文部分内容阅读
目的:探讨CA125、CYFRA21-1、CEA、NSE、AFP联合检测对肺癌的诊、诊断的敏感度以及特异性。方法:对我院收治的确诊为肺癌的患者选取120例作为A组,同期选择肺部良性病变患者61例作为B组,以及50例健康体检患者作为C组,将三组研究对象分别进行CA125、CYFRA21-1、CEA、NSE、AFP的检测。结果:A组患者CA125、CYFRA21-1、CEA、NSE、AFP的血清中含量明显高于B组以及C组(P<0.05);五种标记物联合检测的敏感度明显高于单一标志物的敏感度(P<0.05),但其特异性有明显的降低(P<0.05)。结论:采用CA125、CYFRA21-1、CEA、NSE、AFP联合检测,对肺癌的早期诊断以及治疗预后有较好的指导作用。
Objective: To investigate the sensitivity and specificity of combined detection of CA125, CYFRA21-1, CEA, NSE and AFP in the diagnosis and diagnosis of lung cancer. Methods: 120 patients diagnosed as lung cancer admitted to our hospital were selected as group A, 61 patients with benign lung disease were selected as group B in the same period, and 50 healthy subjects were selected as group C, the three groups of patients were respectively treated with CA125 , CYFRA21-1, CEA, NSE, AFP detection. Results: The serum levels of CA125, CYFRA21-1, CEA, NSE and AFP in group A were significantly higher than those in group B and C (P <0.05). The sensitivity of combined detection of five markers was significantly higher than that of single marker Sensitivity (P <0.05), but its specificity was significantly reduced (P <0.05). Conclusion: The combined detection of CA125, CYFRA21-1, CEA, NSE and AFP has a good guiding role in the early diagnosis of lung cancer and the prognosis of treatment.